L. Bradley Campbell's most recent trade in Amicus Therapeutics Inc was a trade of 1,008,680 Common Stock done at an average price of $14.5 . Disclosure was reported to the exchange on April 27, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale or transfer of securities back to the company at price $ 14.50 per share. | 27 Apr 2026 | 1,008,680 | 0 (0%) | 0% | 14.5 | 14,625,860 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 482,908 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 301,109 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 283,555 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 265,517 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 188,257 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 187,970 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 151,515 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 103,578 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 14.31 per share. | 20 Jan 2026 | 75,000 | 1,021,180 (0%) | 0% | 14.3 | 1,073,183 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.10 per share. | 20 Jan 2026 | 75,000 | 1,096,180 (0%) | 0% | 6.1 | 457,500 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 75,000 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.25 per share. | 26 Dec 2025 | 108,602 | 1,021,180 (0%) | 0% | 14.3 | 1,547,579 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.86 per share. | 15 Dec 2025 | 77,926 | 1,129,782 (0%) | 0% | 10.9 | 846,011 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2025 | 70,426 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.03 per share. | 15 Dec 2025 | 70,426 | 1,207,708 (0%) | 0% | 9.0 | 635,947 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.01 per share. | 01 Dec 2025 | 14,587 | 1,137,282 (0%) | 0% | 10.0 | 146,011 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2025 | 14,587 | 70,426 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.03 per share. | 01 Dec 2025 | 14,587 | 1,151,869 (0%) | 0% | 9.0 | 131,721 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Nov 2025 | 14,587 | 85,013 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.04 per share. | 24 Nov 2025 | 14,587 | 1,137,282 (0%) | 0% | 10.0 | 146,522 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.03 per share. | 24 Nov 2025 | 14,587 | 1,151,869 (0%) | 0% | 9.0 | 131,721 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.90 per share. | 15 Mar 2025 | 13,375 | 1,137,282 (0%) | 0% | 8.9 | 119,038 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 19 Feb 2025 | 400 | 1,150,657 (0%) | 0% | 10 | 4,000 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.03 per share. | 19 Feb 2025 | 400 | 1,151,057 (0%) | 0% | 9.0 | 3,612 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 400 | 99,600 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 137,075 | 1,220,768 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.57 per share. | 11 Feb 2025 | 70,711 | 1,150,657 (0%) | 0% | 9.6 | 676,704 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 482,908 | 482,908 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 266,528 | 1,132,535 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.41 per share. | 02 Jan 2025 | 41,474 | 1,091,061 (0%) | 0% | 9.4 | 390,270 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.31 per share. | 02 Jan 2025 | 20,647 | 866,007 (0%) | 0% | 9.3 | 192,224 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.41 per share. | 02 Jan 2025 | 7,368 | 1,083,693 (0%) | 0% | 9.4 | 69,333 | Common Stock |
| Amicus Therapeutics Inc | Campbell L. Bradley | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.02 per share. | 02 Dec 2024 | 7,500 | 886,654 (0%) | 0% | 10.0 | 75,125 | Common Stock |
| Amicus Therapeutics Inc | Bradley Campbell L. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 7,500 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Campbell Bradley L. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.61 per share. | 02 Dec 2024 | 7,500 | 894,154 (0%) | 0% | 8.6 | 64,575 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.50 per share. | 06 Nov 2024 | 7,901 | 886,654 (0%) | 0% | 12.5 | 98,800 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2024 | 7,901 | 67,100 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.28 per share. | 06 Nov 2024 | 7,901 | 894,555 (0%) | 0% | 12.3 | 97,024 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.61 per share. | 01 Nov 2024 | 7,500 | 894,154 (0%) | 0% | 8.6 | 64,575 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.46 per share. | 01 Nov 2024 | 7,500 | 886,654 (0%) | 0% | 11.5 | 85,960 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 7,500 | 7,500 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.60 per share. | 01 Oct 2024 | 7,500 | 886,654 (0%) | 0% | 10.6 | 79,493 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.61 per share. | 01 Oct 2024 | 7,500 | 894,154 (0%) | 0% | 8.6 | 64,575 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 7,500 | 15,000 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.61 per share. | 03 Sep 2024 | 7,500 | 894,154 (0%) | 0% | 8.6 | 64,575 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 7,500 | 22,500 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.71 per share. | 03 Sep 2024 | 7,500 | 886,654 (0%) | 0% | 11.7 | 87,798 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2024 | 7,500 | 30,000 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.34 per share. | 01 Aug 2024 | 7,500 | 886,654 (0%) | 0% | 10.3 | 77,519 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.61 per share. | 01 Aug 2024 | 7,500 | 894,154 (0%) | 0% | 8.6 | 64,575 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jul 2024 | 6,100 | 37,500 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 05 Jul 2024 | 6,100 | 886,654 (0%) | 0% | 10.0 | 61,029 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.61 per share. | 05 Jul 2024 | 6,100 | 892,754 (0%) | 0% | 8.6 | 52,521 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.61 per share. | 01 Jul 2024 | 1,400 | 888,054 (0%) | 0% | 8.6 | 12,054 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 1,400 | 43,600 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 01 Jul 2024 | 1,400 | 886,654 (0%) | 0% | 10.0 | 14,003 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.61 per share. | 03 Jun 2024 | 7,500 | 894,154 (0%) | 0% | 8.6 | 64,575 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 7,500 | 45,000 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 03 Jun 2024 | 7,500 | 886,654 (0%) | 0% | 10 | 75,000 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 7,500 | 52,500 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.07 per share. | 01 May 2024 | 7,500 | 886,654 (0%) | 0% | 10.1 | 75,524 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.61 per share. | 01 May 2024 | 7,500 | 894,154 (0%) | 0% | 8.6 | 64,575 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 7,500 | 60,000 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.67 per share. | 01 Apr 2024 | 7,500 | 886,654 (0%) | 0% | 11.7 | 87,496 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.61 per share. | 01 Apr 2024 | 7,500 | 894,154 (0%) | 0% | 8.6 | 64,575 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.48 per share. | 15 Mar 2024 | 13,375 | 886,654 (0%) | 0% | 11.5 | 153,545 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.14 per share. | 01 Mar 2024 | 15,833 | 871,219 (0%) | 0% | 13.1 | 208,017 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.28 per share. | 01 Mar 2024 | 8,333 | 887,052 (0%) | 0% | 12.3 | 102,329 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 8,333 | 75,001 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 7,500 | 67,500 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.61 per share. | 01 Mar 2024 | 7,500 | 878,719 (0%) | 0% | 8.6 | 64,575 | Common Stock |
| Amicus Therapeutics Inc | Bradley Campbell L. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 15 Feb 2024 | 4,167 | 871,219 (0%) | 0% | 14 | 58,338 | Common Stock |
| Amicus Therapeutics Inc | Bradley Campbell L. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.56 per share. | 01 Feb 2024 | 15,833 | 875,386 (0%) | 0% | 12.6 | 198,858 | Common Stock |
| Amicus Therapeutics Inc | L. Campbell Bradley | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 8,333 | 83,334 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | L. Campbell Bradley | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.28 per share. | 01 Feb 2024 | 8,333 | 891,219 (0%) | 0% | 12.3 | 102,329 | Common Stock |
| Amicus Therapeutics Inc | Bradley Campbell L. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.61 per share. | 01 Feb 2024 | 7,500 | 882,886 (0%) | 0% | 8.6 | 64,575 | Common Stock |
| Amicus Therapeutics Inc | L. Bradley Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 7,500 | 75,000 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2024 | 28,810 | 927,773 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Bradley Campbell L. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.65 per share. | 09 Jan 2024 | 23,577 | 875,386 (0%) | 0% | 13.6 | 321,826 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.65 per share. | 09 Jan 2024 | 23,577 | 904,196 (0%) | 0% | 13.6 | 321,826 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.44 per share. | 04 Jan 2024 | 7,368 | 898,963 (0%) | 0% | 13.4 | 99,026 | Common Stock |
| Amicus Therapeutics Inc | Bradley Campbell L. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 265,517 | 265,517 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | L. Bradley Campbell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 153,810 | 963,257 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | L. Bradley Campbell | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.53 per share. | 02 Jan 2024 | 41,474 | 906,331 (0%) | 0% | 13.5 | 561,143 | Common Stock |
| Amicus Therapeutics Inc | L. Bradley Campbell | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.24 per share. | 02 Jan 2024 | 15,452 | 947,805 (0%) | 0% | 14.2 | 220,036 | Common Stock |
| Amicus Therapeutics Inc | Bradley Campbell L. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 14.23 per share. | 02 Jan 2024 | 8,333 | 947,805 (0%) | 0% | 14.2 | 118,611 | Common Stock |
| Amicus Therapeutics Inc | L. Campbell Bradley | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 8,333 | 91,667 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | L. Campbell Bradley | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.28 per share. | 02 Jan 2024 | 8,333 | 956,138 (0%) | 0% | 12.3 | 102,329 | Common Stock |
| Amicus Therapeutics Inc | L. Bradley Campbell | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.61 per share. | 02 Jan 2024 | 7,500 | 955,305 (0%) | 0% | 8.6 | 64,575 | Common Stock |
| Amicus Therapeutics Inc | L. Bradley Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 14.24 per share. | 02 Jan 2024 | 7,500 | 947,805 (0%) | 0% | 14.2 | 106,769 | Common Stock |
| Amicus Therapeutics Inc | Campbell L. Bradley | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 7,500 | 82,500 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley Campbell L. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 17,286 | 809,447 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | L. Bradley Campbell | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.08 per share. | 01 Dec 2023 | 11,702 | 792,161 (0%) | 0% | 11.1 | 129,693 | Common Stock |
| Amicus Therapeutics Inc | Bradley Campbell L. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2023 | 11,702 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Campbell L. Bradley | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 01 Dec 2023 | 11,702 | 803,863 (0%) | 0% | 2.9 | 34,404 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 13.39 per share. | 01 Aug 2023 | 20,000 | 798,554 (0%) | 0% | 13.4 | 267,874 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 01 Aug 2023 | 11,700 | 818,554 (0%) | 0% | 2.9 | 34,398 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2023 | 11,700 | 46,802 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 12.51 per share. | 12 Jul 2023 | 6,800 | 806,854 (0%) | 0% | 12.5 | 85,091 | Common Stock |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 12.51 per share. | 12 Jul 2023 | 1,500 | 813,654 (0%) | 0% | 12.5 | 18,759 | Common Stock |